The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
High-dose interleukin-2 (HD IL-2) in the treatment of advanced melanoma: The University of Pittsburgh experience.
Diwakar Davar
No relevant relationships to disclose
Melissa Saul
No relevant relationships to disclose
Ahmad A. Tarhini
Consultant or Advisory Role - Prometheus
Research Funding - Prometheus
An Tran
No relevant relationships to disclose
Kerry Trent
No relevant relationships to disclose
Cindy Sander
No relevant relationships to disclose
John M. Kirkwood
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Merck; Novartis; Vical
Research Funding - Prometheus
Hussein Abdul-Hassan Tawbi
No relevant relationships to disclose